Relapse and Long-Acting Injectable Risperidone: A 1-Year Mirror Image Study with a National Claims Database in Taiwan

Abstract

This 1-year mirror-image analysis with claims-based data demonstrated that RLAI treatment was associated with reductions in relapses and hospital service utilization.

Effectiveness of Oral Antipsychotic versus Long-Acting-Injectable Antipsychotics: A Comparison of Suicidality, Relapse, and Recidivism

“…Our results are consistent with many similar studies that seek to compare the efficacy of OA to LAI medications (Su et al, 2009;Gastpar et al, 2005;Kishimoto et al, 2013;Vincent et al, 2017). The reduction seen in the total number of MH ER visits (~48.6%) is consistent with other studies which have previously documented decreases between ~36% and 73% (Su et al, 2009;Denham & Adamson, 1971;Schooler, 2003).…”

“…The reduction seen in the total number of MH ER visits (~48.6%) is consistent with other studies which have previously documented decreases between ~36% and 73% (Su et al, 2009;Denham & Adamson, 1971;Schooler, 2003). However, in contrast to our results, randomized controlled trials (RCTs) have generally not found statistically significant differences between the efficacy of OA and LAI regimens (Kishimoto et al, 2012;Ostuzzi et al, 2017).…”

“…We believe these are reasonable indicators of patient relapse as the psychiatric disorders included in the study are often linked to extreme symptoms and behaviours including: psychosis, suicidal ideation, violence, drug abuse and others, all of which warrant medical attention (Lafeuille et al, 2013;Chapman et al, 2015;Hogarty and Ulrich, 1998). Repeated relapses in patients has been shown to increase the risk for shorter remission periods and higher severity of future episodes (Su et al, 2009;Sheperd et al, 1989). Poor adherence and/or compatibility with the treatment could therefore increase healthcare costs significantly, given that previous investigations have demonstrated schizophrenia and other disorders that are associated with psychosis account for some of the costliest diseases to treat in Canada (Vincent et al, 2017;Goeree et al, 2005).…”

“…Previous studies have exhibited a reduction in healthcare resource utilization in schizophrenic patients treated with LAI medication (Lafeuille et al, 2013;Koczerginski & Arshoff, 2011;Su et al, 2009;Davis, 1975;Sena et al, 2003;Olivares et al, 2009;Sheperd et al, 1989). At Lakeridge Health Oshawa (LHO), a midsized community hospital in Oshawa, Ontario, Canada, a group of patients with disorders associated with psychosis were switched from OA treatment to LAI regimens, and multiple drug types were included.…”

“…Patients who suffer from psychiatric disorders associated with psychosis relapse despite treatment with antipsychotic medication (Lafeuille et al, 2013), leading to re-hospitalization (emergency room (ER) visits, and admissions), high healthcare costs, and other poor outcomes (Koczerginski & Arshoff, 2011;Su et al, with therapy, such as hallucinations, poor cognition, lack of insight, social stigma and other factors; furthermore, many patients need assistance to take the medication (Haddad et al, 2014). Many antipsychotic medications have been made available in a longacting-injectable (LAI) formulation, in which patients are required to receive an appropriate dosage on a specific recurring timeinterval (Lafeuille et al, 2013).…”